• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday

    6/30/23 10:27:33 AM ET
    $ACCD
    $ALVO
    $APPS
    $ARQT
    Business Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACCD alert in real time by email

    U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.

    • Addentax Group Corp. (NASDAQ:ATXG) shares gained 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms.
    • CymaBay Therapeutics, Inc. (NASDAQ:CBAY) jumped 40% to $10.97.
    • TOP Financial Group Limited (NASDAQ:TOP) shares rose 32.2% to $10.31 after the company reported FY23 financial results.
    • Friedman Industries, Incorporated (NYSE:FRD) gained 19.6% to $11.90 after posting a profit for the fourth quarter.
    • Rackspace Technology, Inc. (NASDAQ:RXT) surged 15.8% to $2.27. Rackspace Technology partnered with Google Cloud to offer cutting-edge generative AI services and solutions using the FAIR practice.
    • MicroVision, Inc. (NASDAQ:MVIS) jumped 12.8% to $4.40.
    • XPeng Inc. (NYSE:XPEV) rose 12.4% to $13.29 after CLSA upgraded the stock from Buy to Outperform and raised the price target from $10 to $13.1. The company, on Thursday. launched G6 Ultra Smart Coupe SUV in China.
    • Alvotech (NASDAQ:ALVO) gained 12.2% to $7.74. The FDA issued a complete response letter to second application for AVT02, biosimilar candidate for Humira.
    • Digital Turbine, Inc. (NASDAQ:APPS) jumped 11.3% to $9.58.
    • Savara Inc. (NASDAQ:SVRA) gained 10% to $2.97.
    • Vitru Limited (NASDAQ:VTRU) rose 9.5% to $17.61.
    • Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) gained 9.4% to $9.12.
    • Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares climbed 9% to $9.98 after the board announced exploration of strategic alternatives to maximize shareholder value.
    • Accolade, Inc. (NASDAQ:ACCD) rose 8.4% to $13.71 after the company reported better than expected first-quarter earnings.
    • Bausch + Lomb Corporation (NYSE:BLCO) climbed 7.8% to $20.68 after the company announced it entered into a definitive agreement with Novartis to acquire XIIDRA.
    • Carnival Corporation (NYSE:CCL) gained 7.8% to $18.50 after Jefferies upgraded the stock from Hold to Buy and raised the price target from $9 to $25.
    • SMART Global Holdings, Inc. (NASDAQ:SGH) rose 7.7% to $28.69 after the company reported better-than-expected third-quarter financial results and issued guidance.
    • GoGreen Investments Corporation (NYSE:GOGN) gained 6.3% to $11.30 after the company announced shareholder approval of business combination with Lifezone Metals.
    • NIO Inc. (NYSE:NIO) rose 6.2% to $9.98.

     

    Read More: Top 3 Energy Stocks Which Could Rescue Your Portfolio This Month

    Get the next $ACCD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACCD
    $ALVO
    $APPS
    $ARQT

    CompanyDatePrice TargetRatingAnalyst
    Bausch + Lomb Corporation
    $BLCO
    10/1/2025$16.00Neutral
    Goldman
    NIO Inc.
    $NIO
    9/23/2025$8.10 → $8.60Buy
    Citigroup
    Alvotech
    $ALVO
    9/23/2025$14.00Hold → Buy
    Deutsche Bank
    NIO Inc.
    $NIO
    9/16/2025$8.50Neutral → Buy
    UBS
    NIO Inc.
    $NIO
    8/26/2025$8.00Neutral → Overweight
    Analyst
    XPeng Inc.
    $XPEV
    8/18/2025$19.00Neutral
    BNP Paribas Exane
    Savara Inc.
    $SVRA
    8/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    Digital Turbine Inc.
    $APPS
    8/6/2025$5.50Underperform → Neutral
    BofA Securities
    More analyst ratings

    $ACCD
    $ALVO
    $APPS
    $ARQT
    SEC Filings

    View All

    Addentax Group Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - ADDENTAX GROUP CORP. (0001650101) (Filer)

    10/7/25 5:00:27 PM ET
    $ATXG
    Professional Services
    Consumer Discretionary

    SEC Form S-8 filed by Friedman Industries Inc.

    S-8 - FRIEDMAN INDUSTRIES INC (0000039092) (Filer)

    10/7/25 4:56:19 PM ET
    $FRD
    Steel/Iron Ore
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

    SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    10/6/25 5:46:39 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $ALVO
    $APPS
    $ARQT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 10:44:05 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $ALVO
    $APPS
    $ARQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Kinsell Joshua covered exercise/tax liability with 5,663 shares, decreasing direct ownership by 2% to 289,007 units (SEC Form 4)

    4 - Digital Turbine, Inc. (0000317788) (Issuer)

    10/10/25 4:04:53 PM ET
    $APPS
    Multi-Sector Companies
    Miscellaneous

    Officer Edwards Larry Todd sold $90,263 worth of shares (4,504 units at $20.04), decreasing direct ownership by 2% to 179,324 units (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    10/6/25 3:15:24 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Watanabe Todd sold $884,649 worth of shares (45,000 units at $19.66), decreasing direct ownership by 5% to 846,440 units (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    10/3/25 5:02:42 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $ALVO
    $APPS
    $ARQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Bausch + Lomb with a new price target

    Goldman initiated coverage of Bausch + Lomb with a rating of Neutral and set a new price target of $16.00

    10/1/25 8:44:08 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Citigroup reiterated coverage on NIO with a new price target

    Citigroup reiterated coverage of NIO with a rating of Buy and set a new price target of $8.60 from $8.10 previously

    9/23/25 10:10:35 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    Alvotech upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Alvotech from Hold to Buy and set a new price target of $14.00

    9/23/25 8:10:17 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $ALVO
    $APPS
    $ARQT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rackspace Technology Receives Silver Award from UK Armed Forces Covenant

    LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rackspace Technology® (NASDAQ:RXT), a leading provider of end-to-end hybrid and AI technology solutions, today announced it has received the UK Armed Forces Covenant's Defence Employer Recognition Scheme (ERS) Silver Award recognizing employers who have shown exceptional support to the armed forces community including reservists, veterans and military families. Employers recognized have gone beyond the UK Armed Forces Covenant commitments to embed supportive employee policies, promote defence values, and advocate for service personnel in the civilian workforce with policies that include: Paid leave for reservist training and mobilisationActive ve

    10/9/25 4:01:00 AM ET
    $RXT
    Computer Software: Programming Data Processing
    Technology

    Holland America Line Goes Glam with Cruising's First Lipstick Blending Bar at Sea

    The new 'Blend Bar' experience allows guests to create a customized lipstick or gloss SEATTLE, Oct. 8, 2025 /PRNewswire/ -- Holland America Line is sailing into style with the launch of Blend Bar — the first lipstick blending bar at sea. Beauty connoisseurs can design and take home a signature lipstick or gloss created on board at the exclusive lipstick lab. The hands-on Blend Bar experience is guided by an expert beauty consultant who will help guests create a wearable memory of their cruise vacation. Blend Bar offers a palette of more than 30 premium pigments, four luxurious

    10/8/25 9:00:00 AM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    SUN PRINCESS NAMED #1 MEGA CRUISE SHIP IN 2025 CONDÉ NAST TRAVELER READERS' CHOICE AWARDS FOR SECOND CONSECUTIVE YEAR

    FORT LAUDERDALE, Fla., Oct. 7, 2025 /PRNewswire/ -- Princess Cruises' stunning Sphere-Class ship, Sun Princess, has once again been recognized as the #1 Mega Cruise Ship in the prestigious Condé Nast Traveler 2025 Readers' Choice Awards. This marks the second consecutive year that Sun Princess has earned the top honor, underscoring her reputation for delivering unforgettable voyages with extraordinary style, innovation, and service. Launched in 2024, as the first of the new Sphere-Class vessels, the 177,882-ton, 4,300-guest Sun Princess quickly captured the hearts of travelers

    10/7/25 10:00:00 AM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    $ACCD
    $ALVO
    $APPS
    $ARQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tang Kevin bought $13,590,000 worth of shares (1,300,000 units at $10.45) (SEC Form 4)

    4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

    8/5/25 5:31:03 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hawkins Richard J bought $98,572 worth of shares (48,225 units at $2.04), increasing direct ownership by 72% to 115,466 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/23/25 2:39:22 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    6/17/25 5:45:01 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $ALVO
    $APPS
    $ARQT
    Financials

    Live finance-specific insights

    View All

    CARNIVAL CORPORATION & PLC ACHIEVES ALL-TIME HIGH FINANCIAL RESULTS WITH NET INCOME OF $1.9 BILLION (ADJUSTED NET INCOME OF $2 BILLION)

    Exceeds guidance and raises full year 2025 outlook for the third time this year MIAMI, Sept. 29, 2025 /PRNewswire/ -- Carnival Corporation & plc ((NYSE/LSE: CCL, NYSE:CUK) announced financial results for the third quarter 2025 and provided an updated outlook for the full year and an outlook for the fourth quarter 2025. Achieved all-time high net income1 of $1.9 billion and adjusted net income1,2 of $2.0 billion.Raised full year 2025 adjusted net income guidance for the third quarter in a row due to improved net yields2 and effective cost & balance sheet management; now expected to be up nearly 55 percent year over year.Delivered record revenues1 of $8.2 billion, a record for the tenth conse

    9/29/25 9:15:00 AM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 29, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its product pipeline which features potential game-changing innovations in each business unit. T

    9/29/25 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Friedman Industries, Incorporated Announces Cash Dividend

    LONGVIEW, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of Friedman Industries, Incorporated, (NASDAQ/GS: FRD) a Texas-based company engaged in metals processing, pipe manufacturing, and metals distribution, declared on September 18, 2025, a cash dividend of $0.04 per share on the Common Stock of the Company. The Company will pay the cash dividend on November 14, 2025 to shareholders of record at the close of business on October 24, 2025. This dividend marks the Company's 215th consecutive quarterly cash dividend since becoming publicly traded in 1972. Dividends are declared at the discretion of the Board and reviewed on a quarterly basis. The Board's desi

    9/18/25 3:00:22 PM ET
    $FRD
    Steel/Iron Ore
    Industrials

    $ACCD
    $ALVO
    $APPS
    $ARQT
    Leadership Updates

    Live Leadership Updates

    View All

    Holland America Line and RWS Global Partner to Bring the Legacy of Bob Fosse and Gwen Verdon to the International Stage for the First Time

    'Fosse and Verdon, The Duet That Changed Broadway' will debut in November, featuring never-before-seen archival footage NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Today, cruise line Holland America Line and RWS Global, the world's leader in live moments across entertainment and sports, announced the debut of "Fosse and Verdon, The Duet That Changed Broadway," an all-new live musical and multimedia tribute celebrating the revolutionary work of Bob Fosse and Gwen Verdon. Developed in collaboration with The Verdon Fosse Legacy®, the production marks the first international staging of their iconic work at sea.

    9/9/25 10:14:00 AM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

    Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration

    9/3/25 7:30:00 AM ET
    $ARQT
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

    REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined the company as VP Investor Relations Scandinavia, based in Stockholm. Patrik Ling has more than 25 years of experience in the life-science industry. Most recently he served as Senior Equity Analyst at the investment bank DNB Carnegie, covering life science companies, including Alvotech. He began his career in marketing and sales of pharmaceuticals, before transitioning to the financial sector, where he was a portfolio manager and equity analyst focusing on the life-s

    8/20/25 6:05:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $ALVO
    $APPS
    $ARQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Savara Inc.

    SC 13G - Savara Inc (0001160308) (Subject)

    11/27/24 11:01:58 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/14/24 7:50:59 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/14/24 7:34:26 PM ET
    $ACCD
    Business Services
    Consumer Discretionary